Edit
Immune Regulation Limited
https://immuneregulation.com/Last activity: 23.09.2020
Active - Reference to Revolo Biotherapeutics
Employees: 11-50
Total raised: $52.05M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | NCL Techno... | ncltv.co.u... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.09.2020 | Series B | $52.05M | - |
Mentions in press and media 6
| Date | Title | Description |
| 23.09.2020 | SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing | Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies. London UK and Boston USA... Immune Regulation Limited, a US and UK based clinical stage biotechn... |
| 23.09.2020 | SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing | SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing 23-09-2020 Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies.... |
| 22.09.2020 | Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing | Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies (London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a... |
| 22.09.2020 | Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing | Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies (London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a... |
| 21.09.2020 | Immune Regulation Limited: Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing | DGAP-News: Immune Regulation Limited / Key word(s): Financing Immune Regulation Limited: Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing 21.09.2020 / 09:00 The issuer is solely responsible for the co... |
| 21.09.2020 | Immune Regulation Raises £40.6M in Series B Equity Financing | Immune Regulation Limited, a US and UK based clinical stage biotechnology company, closed a $40.6m Series B funding round. The round was led by Morningside Ventures, alongside existing shareholders including London based 24Haymarket. The in... |